Fulcrum Therapeutics Inc
NASDAQ:FULC
| Market Cap (Intraday) | 397.74M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $13.31 |
| 50-Day MA | $12.55 |
| 200-Day MA | $13.04 |
Fulcrum Therapeutics, Inc. Stock, NASDAQ:FULC
26 Landsdowne Street, Cambridge, Massachusetts 02139
United States of America
Phone: +1.617.651.8851
Number of Employees: 73
Description
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.